[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bronchiectasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bronchiectasis":26},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,58,0,25,[9,48,81,105,127,137,166,197,226,250,273,306,332,353,380,398,422,438,462,485,512,542,563,588,615],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":4,"leadSponsor":44,"locationsCount":47},"100053333","natural-history-of-bronchiectasis-100053333",false,"NCT00943514","Natural History of Bronchiectasis","* PARTICIPANT INCLUSION CRITERIA:\n\n  1. Children age 5 years and above and adults referred to the NIH with chronic or recurring respiratory infections will be eligible for participation.\n  2. Males and females will be considered without regard to race or ethnicity or upper age limit.\n  3. Emphasis will be primarily on non CF bronchiectasis for elucidation of mechanisms of infection susceptibility. However, select patients with cystic fibrosis or acquired immune defects (such as HIV) may be studied if relevant host defects are suspected, if needed for comparison purposes, or to evaluate and study the management of chronic pathogen associated conditions such as nontuberculous mycobacterial infections or allergic bronchopulmonary aspergillosis.\n  4. Subjects must have a primary or referring physician\n  5. Subjects must be willing to have samples stored\n\nINCLUSION CRITERIA FOR RELATIVES:\n\nAs a part of this protocol we may obtain blood, sputum, urine, or buccal swabs from some blood relatives of patients on the study, with the hope of isolating and characterizing the primary host defense defect(s) or genetic links responsible for airway infection susceptibility and\u002For bronchiectasis seen within families. Male and female relatives will be accepted without limitation due to age. These relatives may have pertinent disease-related history obtained, but will neither receive treatment nor have any other protocol procedures done unless they are enrolled on the study.\n\nPARTICIPANT EXCLUSION CRITERIA:\n\n1. We wish to avoid enrolling subjects, especially children, who have common respiratory problems (aeroallergen sensitivity, asthma, gastric esophageal reflux) that are not associated with an underlying abnormality in host defenses. Evidence of significance of chronic or recurring infections suggestive of an underlying airway surface or systemic host defense defect should be documented by one or more of the following: a) sinus or lower airway cultures positive for bacterial, fungal, or mycobacterial pathogens characteristic of these defects; or b) radiographic evidence of sinusitis with mucosal thickening and\u002For air-fluid levels; or c) radiographic evidence of bronchiectasis; d) severity of otitis media requiring placement of tympanic membrane pressure equalization tubes; e) severity of sinusitis requiring surgical intervention.\n2. Patients who are unable or unwilling to provide informed consent either directly or via appropriately designated surrogate.\n3. Any patient who, in the opinion of the Investigator, is unable or unwilling to comply with regular follow-up or is unlikely to provide pertinent information regarding disease progression or response to treatment may be excluded from longitudinal follow-up.\n\nPARTICIPATION OF CHILDREN:\n\nChildren under the age of 5 will be excluded from this protocol due to the difficulty of performing pertinent assays in infants and younger children, difficulty distinguishing significance of respiratory infections which occur commonly in younger children, and the lack of adequate facilities and equipment for management of children younger than 2 years.",true,"ALL","5 Years","100 Years",{"count":21,"type":22},900,"ESTIMATED","OBSERVATIONAL","Background:\n\n* Bronchiectasis is a disease characterized by airways that are inflamed, abnormally dilated, and chronically infected. Individuals with bronchiectasis have a history of chronic and recurring respiratory infections. Depending on the underlying cause, these infections may involve the entire respiratory tract, resulting in sinus, ear, and lung disease.\n* Bronchiectasis continues to be a significant problem in developing countries and in specific groups of individuals, particularly in people who have cystic fibrosis. Although treatments are available or under development for bronchiectasis related to cystic fibrosis, many of the disease-specific treatments may not be effective for bronchiectasis not related to cystic fibrosis.\n\nObjectives:\n\n\\- To study the natural history of bronchiectasis to identify inherited and immune factors that may explain why certain individuals have chronic recurring infections.\n\nEligibility:\n\n* Individuals 5 years of age and older who have an established diagnosis of bronchiectasis or a history of chronic\u002Frecurring respiratory infections.\n* Direct family members (e.g., parents, siblings, children) of patients in the study may also be asked to participate.\n\nDesign:\n\n* Potential participants will be screened with an initial clinic evaluation and full medical history, as well as a general quality of life and respiratory symptom questionnaire.\n* The following standard procedures may be done as part of the study: air sampling from the nose; imaging studies, which may include an x-ray or computed tomography (CT), lung function tests; and collection of samples of blood, urine, and sputum (phlegm or mucus). Other tests may be performed as required by the researchers, and will be explained to patients as needed.\n* Both patients and relatives (if asked to participate) will provide the following samples: blood or buccal (cheek swab) cells for genetic testing, sputum, and urine.\n* To prevent infections and potential disease progression, patients may receive standard medical care and treatment for bronchiectasis and related infections during this protocol.",[26,27,28,29],"Bronchiectasis","Cystic Fibrosis","Autoimmune Disease","Common Variable Immunodeficiency",[31,32,33,34,35,36],"Variant Cystic Fibrosis","Bronchopulmonary Mycosis","Airway Infection Susceptibility","Chronic Respiratory Infection","Primary Ciliary Dyskinesia","Natural History","RECRUITING","2026-07-10",{"date":40,"type":41},"2026-07-13","ACTUAL",{"date":43,"type":41},"2009-08-01",{"name":45,"class":46},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100608399","phase-2-a-study-to-assess-the-effectiveness-and-safety-of-gsk3862995b-in-adults-with-bronchiectasis-100608399","NCT07201051","A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis","A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Investigate Efficacy, Safety, Immunogenicity, and Pharmacokinetics, of GSK3862995B in Participants With Bronchiectasis","Inclusion Criteria:\n\n* Body mass index (BMI) between 18-35 kilograms per square meters (kg\u002Fm\\^2)\n* Clinical history consistent with bronchiectasis (cough, chronic sputum production, and\u002For recurrent respiratory infections) that is confirmed on chest computed tomography (CT)\n* Meet one of the two criteria:\n\n  * In the 12 months prior to screening, have had 2 or more documented pulmonary exacerbations that required a new antibiotic prescription by a physician or 1 pulmonary exacerbation that required hospitalization; or\n  * In the 12 months prior to screening, have had 0 or 1 pulmonary exacerbation and a QOL-B RSS of less than (\\\u003C)50 at screening\n* Current sputum producers\n* Post-bronchodilator FEV1 greater than or equal to (\\>=) 30 percent (%) or greater of predicted normal value\n* Non-smokers or former cigarette smokers\n* Males and females of childbearing and non-childbearing potential\n* A female participant is eligible to participate if she is not pregnant or breastfeeding\n* Is a Woman of non-childbearing potential (WONCBP) or is a Woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective, with a failure rate of \\\u003C1\n* A WOCBP must have a negative highly sensitive serum pregnancy test within 28 days before the first dose of study intervention\n* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the Informed consent form (ICF) and in this protocol\n\nExclusion Criteria:\n\n* Participants with a primary diagnosis of asthma or Chronic Obstructive Pulmonary Disorder (COPD) as judged by the investigator\n* Bronchiectasis due to cystic fibrosis, alpha-1-antitrypsin deficiency, common variable immunodeficiency, hypogammaglobinemia, or traction bronchiectasis due to fibrotic lung disease\n* Active non-tuberculosis mycobacterial (NTM) lung infection on treatment or meeting ATS\u002FInfectious Diseases Society of America (IDSA) criteria for active lung infection\n* Active tuberculosis, untreated latent Tuberculosis (TB), invasive fungal lung infections or allergic bronchopulmonary aspergillosis needing treatment\n* Participant uses long-term oxygen therapy for more than 12 hours per day\n* Participants with an acute lower respiratory tract pulmonary infection needing treatment or pulmonary exacerbation within 4 weeks of the screening visit.\n* Participant has a past or current medical condition(s) or disease(s) that is\u002Fare not well controlled and, which in the judgment of the Investigator, may affect participant safety or affect study endpoints\n* Participants with an unstable cardiac disease, myocardial infarction, Cerebrovascular Accident (CVA), stroke or New York Heart Association Class III or IV heart failure within 12 months prior to screening\n* Participants with clinically significant abnormal Electrocardiogram (ECG) at screening which in the judgment of the Investigator, may affect participant safety or affect study endpoints\n* Significant allergies to humanized monoclonal antibodies\n* Participants with a history of lymphoma, leukemia, or any malignancy within the past 5 years, except for basal cell or squamous epithelial carcinomas of the skin that have been resected for cure with no evidence of recurrence or metastatic disease for 1-year\n* A known or suspected immunodeficiency that has led to opportunistic infections, recurrent invasive infections, or prolonged infections that suggest an underlying immunocompromised state by the judgement of the investigator. Positive HIV antibody test\n* Alanine aminotransferase (ALT) \\>2x Upper limit of normal (ULN)\n* Total bilirubin \\>1.5xULN; Participants with Gilbert's syndrome can be included with total bilirubin \\>1.5xULN as long as direct bilirubin is less than or equal to (\\\u003C=)1.5xULN\n* Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)\n* Presence of hepatitis B surface antigen (Hepatitis B surface antigen \\[HBsAg\\]) and\u002For hepatitis B core antibody (Hepatitis B core antibody \\[HBcAb\\]) at screening or within 3 months prior to first dose of study intervention\n* Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention\n* Positive hepatitis C Hepatitis B core antibody (RNA) test result at screening or within 3 months prior to first dose of study intervention\n* Corrected QT interval (QTc) \\>450 milliseconds (msec) at screening visit based on the average of triplicate ECGs The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.","18 Years","85 Years",{"count":58,"type":22},446,"INTERVENTIONAL",[61],"PHASE2","This study is designed to find out how effective and safe a new drug, GSK3862995B, is for adult participants with bronchiectasis, a chronic lung disease. The study will also test how the body processes the drug and to check for any immune reactions. Participants will be divided into groups randomly to receive either one of two different doses of the study drug or a placebo. The main goal of the study is to see how well the drug works compared to the placebo in helping those with bronchiectasis.",[26],[65,26,66,67,68,69],"GSK3862995B","Efficacy","Safety","Immunogenicity","Pharmacokinetics","2026-07-01",{"date":72,"type":41},"2026-07-02",{"date":74,"type":41},"2025-10-30",{"date":76,"type":22},"2027-12-10",{"name":78,"class":79},"GlaxoSmithKline","INDUSTRY",45,{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":59,"phases":91,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100583174","phase-3-the-airtivity-study-a-study-to-find-out-whether-bi-1291583-helps-people-with-bronchiectasis-100583174","NCT06872892","The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis","A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of BI 1291583 2.5 mg Administered Once Daily for up to 76 Weeks in Patients With Bronchiectasis (The AIRTIVITY™ Study)","Inclusion criteria:\n\n* Male or female participants. Woman of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per International Council of Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1 % per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the participant information.\n* Signed and dated written informed consent and assent, if applicable, prior to admission to the study, in accordance with GCP and local legislation.\n* Age of participants when signing the informed consent\u002Fassent ≥12 years.\n\n  \\-- Adolescents need to weigh at least 35 kg at Visit 1.\n* Clinical history consistent with bronchiectasis (e.g. cough, chronic sputum production, recurrent respiratory infections) and investigator confirmed diagnosis of bronchiectasis by CT scan where bronchiectasis has been documented by a radiologist.\n\nParticipants whose past CT scan image records are not available will undergo a chest CT scan during Screening. Historical scans must not be older than five years.\n\n* Adult participants should be able to produce sputum for Pseudomonas aeruginosa assessment during the screening period.\n* History of documented pulmonary exacerbations (assessed and recorded by the investigator) requiring antibiotic treatment. In the 12 months before Visit 1, participants must have had either:\n\n  * at least 2 exacerbations, or\n  * at least 1 exacerbation and an St. George's Respiratory Questionnaire (SGRQ) Symptoms score of \\>40 at screening Visit 1 (adults only)\n  * at least 1 exacerbation and high symptom burden according to the investigator's judgement (adolescents only) For participants on oral or inhaled antibiotics as chronic treatment for bronchiectasis and participants on Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy (CFTR-MT), at least one exacerbation must have occurred since initiation of antibiotics or CFTR-MT.\n\nExclusion criteria:\n\n* Any new or newly diagnosed condition of primary or secondary immunodeficiency within 1 year before randomisation.\n* Allergic bronchopulmonary aspergillosis being treated or requiring treatment.\n* Tuberculosis or non-tuberculosis mycobacterial infection being treated or requiring treatment\n* Any findings in the medical examination and\u002For laboratory value assessed at Screening Visit 1 or during screening period, that in the opinion of the investigator may put the participant at risk by participating in the trial.\n* Any clinically relevant (at the discretion of the investigator) acute respiratory infection or ongoing pulmonary exacerbation at screening visit or during the screening unless recovered in the opinion of the investigator prior to Visit 2.\n* Any relevant pulmonary, gastrointestinal, hepatic, renal, cardiovascular, metabolic, immunological, hormonal, or other disorder that, in the opinion of the investigator, may put the participant at risk by participating in the study.\n* Major surgery (major according to the investigator's assessment) performed within 6 weeks prior to randomisation or scheduled during trial period.\n* Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated in situ non-melanoma skin cancers or in situ carcinoma of uterine cervix.\n* Evidence or medical history of moderate or severe liver disease (Child-Pugh score B or C hepatic impairment).\n* estimated Glomerular Filtration Rate (eGFR) according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula (adults) or Chronic Kidney Disease Under 25 (CKiD-U25) (adolescents) \\\u003C30 mL\u002Fmin at Visit 1.\n* Previous treatment with a dipeptidyl peptidase-1 (DPP1) (Cathepsin C (CatC)) inhibitor. (Note: Participants that were randomised and only received placebo in studies with DPP1 (CatC) inhibitor are allowed.) Further exclusion criteria apply.","12 Years",{"count":90,"type":22},1755,[92],"PHASE3","This study is open to adults and adolescents aged 12 to under 18 with bronchiectasis. People can participate in this study if they produce sputum and have had flare-ups (also called exacerbations).\n\nThe purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis. Participants are put into 2 groups randomly, which means by chance. One group takes BI 1291583 tablets and the other group takes placebo tablets. A placebo tablet looks like the BI 1291583 tablet but does not contain any medicine. Participants take 1 tablet once a day for up to 1 year and 6 months.\n\nParticipants are in the study for up to 1 year and 8 months. During this time, participants visit the study site up to 10 times and get about 13 phone calls from the site staff. Participants regularly complete a diary on a smartphone about their bronchiectasis symptoms and study doctors regularly check for any changes. The study doctors document when participants experience flare-ups. The number of flare-ups is compared between the participants who receive BI 1291583 and those who receive the placebo. The study doctors also regularly check participants' health and take note of any unwanted effects.",[26],"2026-06-23",{"date":97,"type":41},"2026-06-24",{"date":99,"type":41},"2025-06-09",{"date":101,"type":22},"2028-10-12",{"name":103,"class":79},"Boehringer Ingelheim",494,{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":56,"enrollmentInfo":113,"targetDuration":4,"studyType":59,"phases":115,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":4},"100637229","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-chf10196-tablets-florensocatib-compared-with-placebo-in-male-and-female-participants-12-to-85-years-of-age-with-bronchiectasis-100637229","NCT07577804","A Study to Evaluate the Efficacy and Safety of CHF10196 Tablets (Florensocatib) Compared With Placebo in Male and Female Participants 12 to 85 Years of Age With Bronchiectasis","A Phase III, Randomised, Double-blind, Two-arm Study to Investigate the Efficacy and Safety of Treatment With CHF10196 Tablets (Florensocatib) Compared With Placebo for up to 78 Weeks, Followed by an Open-label Extension, in Male and Female Participants 12 to 85 Years of Age With Bronchiectasis","FABLE","Inclusion Criteria for Main Study:\n\n1. Signed and dated informed consent obtained prior to any study-related procedure; Adolescents: Written informed consent obtained from the parent(s)\u002Flegally authorised representative(s) (according to the local regulation) and written or verbal assent by the participant (when appropriate), obtained prior to any study-related procedures;\n2. Adults: Male or female participant ≥18 and ≤85 years of age; Adolescents: Male or female participant ≥12 and \\\u003C18 years of age;\n3. Adults: BMI (body mass index) \\>18.5 kg\u002Fm² at screening; Adolescents: Body weight \\>30 kg at screening;\n4. Clinical history consistent with bronchiectasis (cough, chronic sputum production, and\u002For recurrent respiratory infections) confirmed by centralised reading of a chest CT, not more than 5 years old demonstrating bronchiectasis affecting 1 or more lobes; Note: If no recent chest CT is available, or if the records\u002Freport is not available, a new CT chest will be performed during the screening period;\n5. A history of at least 2 pulmonary exacerbations treated with antibiotics, or 1 pulmonary exacerbation treated with antibiotics with additional risk factors (SGRQ Symptoms score at screening \\>40) in the past 12 months prior to screening; Adolescents: A history of at least 1 pulmonary exacerbation in the 12 months prior to screening;\n6. Post-bronchodilator FEV1 ≥30% of the predicted value, calculated using the Global Lung Function Initiative 2012 reference equations; Note: in case post-bronchodilator spirometry quality is not judged satisfactory as per ATS\u002FERS acceptability and usability criteria\\*, it may be re-checked on the same day (after a sufficient period of rest) or once before randomisation if it cannot be performed on the same day;\n7. Participants may either be:\n\n   * on stable background therapy for at least 3 months prior to screening;\n   * not on background therapy at screening and not planning to start background therapy;\n8. Able to provide sputum at screening (adults only);\n9. Cooperative attitude and ability to read\u002Fwrite, perform all study-related procedures, and use electronic device, ability to understand the risks involved;\n10. If female, the participant must be of non-childbearing potential, surgically sterile, postmenopausal, or she and her partner must use adequate methods of contraception\\*\\* during the study and for 90 days after the last dose of study intervention. Participants must not donate eggs during the study and for 90 days after the last dose of IMP (investigational medicinal product); Note: In case of hormonal contraception, an additional non-hormonal method (barrier method, preferably male condom) is required. The status of adolescent females being not of childbearing potential at screening will be monitored at each further visit (except the Follow-up visit);\n11. If male, the participant and his partner must agree to use adequate methods of contraception\\*\\* during the study and for at least 90 days after the last dose of study intervention.\n\nInclusion Criteria for OLE (Extension) Study:\n\n1. Participant's written informed consent for the OLE Phase obtained prior to any study-related procedures of the OLE Phase; Adolescents: Written informed consent for the OLE Phase obtained from the parent(s)\u002Flegal representative(s) (according to the local regulation) and written or verbal assent by the participant (when appropriate), obtained prior to any study-related procedures of the OLE Phase;\n2. Participants (adults or adolescents) who completed the treatment period of the Main Phase\n3. Participants with study intervention compliance ≥70% during the Main Phase\n4. If female, the participant must be of non-childbearing potential, surgically sterile, postmenopausal, or she and her partner must use adequate methods of contraception\\* during the study and for 90 days after the last dose of study intervention. Participants must not donate eggs during the study and for 90 days after the last dose of study intervention; Note: In case of hormonal contraception, an additional non-hormonal method (barrier method, preferably male condom) is required. The status of adolescent females being not of childbearing potential at screening will be monitored at each further visit (except the Follow-up visit);\n5. If male, the participant and his partner must agree to use adequate methods of contraception\\* during the study and for at least 90 days after the last dose of study intervention. Participants must not donate sperm during the study and for 90 days after the last dose of study intervention.\n\nExclusion Criteria for Main Study:\n\n1. Participants who have experienced any degree of pulmonary exacerbation or are experiencing a pulmonary exacerbation within 4 weeks prior to screening or during the screening period; Note: Participants can be rescreened only after recovery and 4 weeks after the last dose of antibiotic treatment;\n2. Current diagnosis of CF (cystic fibrosis) as determined by Investigator;\n3. Known history of invasive opportunistic infections (such as but not limited to histoplasmosis, pneumocystosis, or aspergillosis) and\u002For abnormally frequent or prolonged infections suggesting an immunocompromised status judged incompatible with the introduction of a DPP1 inhibitor by the Investigator;\n4. Diagnosis of A1ATD -Alpha-1-antitrypsin deficiency- (defined as A1AT serum level \\\u003C110 mg\u002FdL) currently being treated with augmentation therapy; Note: A prior test result of A1AT serum level to confirm the diagnosis will be acceptable;\n5. Participants with a diagnosis of non-tuberculosis mycobacteria, pulmonary infection or TB (tuberculosis), or allergic bronchopulmonary aspergillosis currently being treated or requiring treatment as determined by the Investigator;\n6. Participants receiving a systemic immunosuppressive therapy for the treatment of an autoimmune disease;\n7. History of malignancy in the past 5 years (excluding cured basal cell carcinoma of the skin, carcinoma in situ and papillary thyroid carcinoma) or treatment of malignancy in the past 5 years;\n8. Have significant haemoptysis (≥300 mL or requiring blood transfusion) within 4 weeks prior to screening or during the screening period;\n9. Participants with a severe concomitant disease or disorder that, in the opinion of the Investigator, may put the participant at risk by participating in the study, or interfere with the participant's treatment, assessment, or influence the results of the study, or have compliance issues with the study. Examples include, but are not limited to, cardiovascular conditions (e.g. NYHA Class III or IV cardiac failure), pulmonary conditions (e.g. severe pulmonary fibrosis or lung transplantation), infectious diseases (e.g. severe COVID-19 infection), gastrointestinal conditions, hepatobiliary conditions (e.g. Child-Pugh class B or C), severe renal conditions (e.g. severe nephrotic syndrome), neurological conditions (e.g. demyelinating diseases), musculoskeletal, endocrine, metabolic or psychiatric conditions;\n10. Have elevated liver function test results (ALT or AST \\>2x ULN) or have a bilirubin \\>1.5x ULN at screening (isolated bilirubin \\>1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin \\\u003C35%);\n11. Have an abnormal renal function test result (eGFR \\\u003C60 mL\u002Fmin by CKD-EPI formula for adults or CKiD-U25 formula for adolescents) at screening\n12. Participants with an absolute blood neutrophil count \\\u003C1000\u002F mm3 at screening;\n13. Participants with a history of alcohol or drug abuse within 6 months prior to screening as per DSM V criteria;\n14. Clinically significant abnormal laboratory values at screening that, in the opinion of the Investigator, may put the participant at risk by participating in the study, or interfere with the participant's treatment or assessment, or influence the results of the study;\n15. Blood donation or blood loss (≥450 mL) less than 2 months prior to screening;\n16. Participants who currently smoke tobacco or who stopped smoking within 3 months prior to screening or who are not willing to abstain from smoking for the duration of the trial; Note: any form of smoking (cigarettes, e-cigarettes, vaping, cannabis) is forbidden during the whole trial\n17. Introduction of new chronic treatment for NCFBE - Non-cystic fibrosis bronchiectasis- (oral or inhaled antibiotics, ICS (inhaled corticosteroids), or low-dose oral steroids\\*), if started \\\u003C3 months prior to screening or during the screening period\n\n    \\*Low-dose oral steroids defined as \\\u003C10 mg\u002Fday of prednisone or equivalent\n18. Use of any immunomodulatory agents (including but not limited to: bortezomib, ixazomib, thalidomide, cyclophosphamide, mycophenolate, Janus kinase inhibitors, IFN-γ, and azathioprine) or chronic treatment with high-dose oral steroids\\* within 4 weeks prior to screening or during the screening period\n\n    \\*High-dose oral steroids defined as ≥10 mg\u002Fday of prednisone or equivalent\n19. Use of strong CYP3A inducers (including but not limited to: apalutamide, carbamazepine, enzalutamide, mitotane, phenytoin, rifampicin) within 4 weeks prior to screening or during the screening period\n20. Previous treatment with another DPP1 (Dipeptidyl peptidase 1) inhibitor within 6 months before screening or during the screening period Note: participants who were randomised and only received placebo in studies with DPP1 inhibitor are allowed;\n21. Participant expected to take prohibited concomitant medications during the study\n22. Received any live attenuated vaccine within 4 weeks prior to randomisation Note: Recent administration of a live vaccine should be checked at screening. If a live vaccine has been administered, the participant should wait for 4 weeks prior to being randomised;\n23. Participants with medical conditions associated with periodontal disease (to be evaluated by a periodontist or dentist), defined as any tooth that can potentially cause pain or infection as noted in the oral exam unless they are corrected before randomisation visit (e.g. pulp necrosis); severe periodontal disease defined as having pocket depth measurements ≥6 mm on ≥2 teeth; Class 3 mobility or Class 3 furcation involvement; or scheduled tooth extraction during the study period;\n24. Participants with medical conditions known to be associated with the onset of non-hereditary palmoplantar keratosis should be carefully evaluated by the Investigator. The presence, severity, and clinical significance of such conditions must be assessed to determine their relevance to study eligibility. Examples include hypothyroidism, myxoedema, chronic lymphoedema, acrocyanosis, livedo reticularis, psoriasis, lichen planus, reactive arthritis (Reiter's disease\u002Fkeratoderma blennorrhagicum), pityriasis rubra pilaris, atopic dermatitis, chronic hand or contact dermatitis, chronic dermatophytosis, chloracne, extensive verruca vulgaris, and keratoderma climactericum;\n25. Medications that may cause palmoplantar keratoderma (including, but not limited to, BRAF inhibitors, MEK inhibitors, selected tyrosine kinase inhibitors, systemic retinoids, and capecitabine) within 4 weeks prior to randomisation\n26. Established diagnosis of hepatitis B or hepatitis C infection. Participants who have gained immunity for HBV infection after vaccination are eligible (HBsAg negative, HBsAb positive and HBcAb negative). Participants with positive HBcAb are eligible only if HBV DNA level is undetectable. Participants positive for HCV antibody are eligible only if HCV RNA is negative;\n27. Known HIV infection or positive serology test at screening;\n28. Known intolerance and\u002For hypersensitivity to DPP1 inhibitors or any of the excipients contained in the formulation used in the trial. A history of discontinuation of DPP1 inhibitors due to an adverse drug reaction is exclusionary;\n29. Clinical diagnosis of Papillon-Lefèvre syndrome;\n30. Abnormal and clinically significant 12-lead ECG at screening or prior to randomisation that results in an active medical problem, which may impact the safety of the participant, per the Investigator's judgement. Male participants with QTcF \\>450 ms and female participants with QTcF \\>470 ms cannot be enrolled (not applicable for participants with permanent atrial fibrillation and for participants with pacemakers). For participants aged 12 to \\\u003C18 years, QTcF values should be interpreted using age-appropriate normative reference ranges;\n31. Participation in other investigational trial: participants who have received an investigational drug within 1 month or 5 half-lives of the previous administered product (whichever is longer) prior to screening, or participants who have been previously randomised in the present trial, or participants who are currently participating in another clinical trial;\n32. For females only (adult or adolescent): pregnant or lactating women, where pregnancy is defined as the state of a female after conception and until termination of the gestation, confirmed by a positive serum β-hCG laboratory test. Both serum and urine pregnancy tests are to be performed at screening, and a urine pregnancy test is to be performed prior to randomisation;\n33. Participants legally incapacitated or participants accommodated in an establishment as a result of an official or judicial order.\n\nExclusion Criteria for OLE (Extension) Study:\n\n1. Pregnant or lactating woman;\n2. ADRs\\*: participants who experienced an ADR (defined as an AE assessed by the Investigator as possibly related to the IMP) during the Main Phase should not be enrolled in the OLE Phase unless the Investigator considers that the AE would not prevent them from safely and effectively participating in the OLE Phase;\n3. Ongoing SAEs\\*: participants with ongoing SAEs at the time of the last visit of the Main Phase should not be enrolled in the OLE Phase unless the Investigator considers that the ongoing SAE would not prevent them from safely and effectively participating in the OLE Phase;\n4. Changes in medical history: any clinically significant changes in participant's medical history, physical examination\u002Fvital signs\u002Flaboratory analysis; concomitant therapies, documented in the Main Phase or any newly identified disease or condition that might, in the judgement of the Investigator, place the participant at undue risk;\n5. Any use of prohibited medications during the Main Phase that requires to be prolonged during the OLE Phase.",{"count":114,"type":22},904,[92],"This study aims to find out whether the tablet CHF10196 is safe and effective for people with non-cystic fibrosis bronchiectasis, a long-term lung disease that causes widened airways, mucus buildup, infections, and flare ups of symptoms. The main goal is to see whether CHF10196 can reduce the number of lung flareups each year compared with placebo. The study will also assess whether it can improve lung function, quality of life, and overall safety.\n\nThe study has two phases. In the first phase, participants receive either CHF10196 tablets or placebo without knowing which one they are taking. In the second phase, all participants receive CHF10196 so its long-term safety can be further studied. Adults aged 18 to 85 years and adolescents aged 12 to under 18 years can take part, while continuing their usual stable bronchiectasis treatment.\n\nUp to about 2.5 years of participation are planned. Around 904 participants will be enrolled, with regular clinic visits and phone check ins. In the first phase, participants take either CHF10196 or inactive tablets once daily; in the second phase, everyone takes CHF10196 once daily. Temporary treatment interruptions are allowed if needed, and participants who stop treatment early may still continue study visits, depending on the study phase.",[26],"NOT_YET_RECRUITING","2026-06-19",{"date":97,"type":41},{"date":122,"type":22},"2026-11",{"date":124,"type":22},"2030-04",{"name":126,"class":79},"Chiesi Farmaceutici S.p.A.",{"id":128,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":130,"keywords":131,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":4,"leadSponsor":136,"locationsCount":47},"100128676",{"count":21,"type":22},[26,27,28,29],[31,32,33,34,35,36],"2026-06-18",{"date":134,"type":41},"2026-06-22",{"date":43,"type":41},{"name":45,"class":46},{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":59,"phases":147,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":47},"100466247","thermotherapy-against-persistent-bacterial-lung-infections-100466247","NCT05351242","THERMotherapy Against Persistent Bacterial LUNG Infections","Thermotherapy Against Persistent Bacterial LUNG Infections","THERMA-LUNG","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Competent and capable\n* FEV1\\>1,0 L\n* Have had a positive culture from sputum or BAL min. 2 times in the last 24 months for bacteria of the species: Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Staphylococcus aureus, Haemophilus influenzae, Achromobacter xylosoxidans, Klebsiella oxytoca or Klebsiella pneumoniae. In addition, min. 1 positive culture after treatment with antibiotics\n* Willing to go to a sauna (min. temperature of 85℃ for at least 7 minutes) four times weekly for six months or avoid going to a sauna for six months\n\nExclusion Criteria:\n\n* Allergy to lidocaine and\u002For midazolam\n* Contraindications to bronchoscopy\n* Previous severe laryngospasm (intubation requiring)\n* Pregnancy\u002Fbreastfeeding\n* Severe linguistic problems or inability to give informed consent\n* Severe mental illness that is not controlled with medication. NB: Patients with controlled mental illness can be included and will be asked on an equal footing as others",{"count":146,"type":22},150,[148],"NA","The aim of this study is to determine whether an intervention with frequent thermotherapy will be able to reduce the amount of colonizing bacteria in the bronchoalveolar lavage sample and eradicate the colonizing bacteria.",[151,26,152,153,154,155],"Lung Diseases, Obstructive","Asthma","Copd","Chronic Obstructive Pulmonary Disease","Chronic Lung Infections","2026-06-15",{"date":158,"type":41},"2026-06-17",{"date":160,"type":22},"2026-10-01",{"date":162,"type":22},"2029-12-31",{"name":164,"class":165},"Chronic Obstructive Pulmonary Disease Trial Network, Denmark","OTHER",{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":59,"phases":176,"briefSummary":177,"conditions":178,"keywords":180,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":47},"100642260","hypertonic-saline-inhalation-for-nontuberculous-mycobacterial-lung-disease-100642260","NCT07647575","Hypertonic Saline Inhalation for Nontuberculous Mycobacterial Lung Disease","A Randomized Controlled Trial of Early Versus Delayed Hypertonic Saline Inhalation in Treatment-Naïve Nontuberculous Mycobacterial Lung Disease","HiNTM","Inclusion Criteria:\n\n1. Adults aged 18 years or older.\n2. Diagnosis of nontuberculous mycobacterial lung disease (NTM-LD) according to ATS\u002FERS\u002FESCMID\u002FIDSA diagnostic criteria, including compatible clinical symptoms, radiographic findings, and microbiological evidence.\n3. Not receiving anti-NTM antibiotic treatment at the time of screening.\n4. Able and willing to provide written informed consent.\n5. Able to perform nebulized inhalation therapy using a mesh nebulizer at home.\n\nExclusion Criteria:\n\n1. Active tuberculosis.\n2. Human immunodeficiency virus (HIV) infection.\n3. Receiving active treatment for malignancy.\n4. Uncontrolled asthma.\n5. Frequent or clinically significant hemoptysis.\n6. History of intolerance, bronchospasm, or hypersensitivity during inhalation testing with hypertonic saline.\n7. Inability to prepare a mesh nebulizer or perform inhalation therapy at home.\n8. Any condition that, in the opinion of the investigator, would make participation unsafe or interfere with study participation.",{"count":175,"type":22},262,[148],"This multicenter randomized controlled trial evaluates the clinical and microbiological effects of inhaled 3% hypertonic saline in treatment-naïve patients with nontuberculous mycobacterial lung disease (NTM-LD). Participants are randomized in a 1:1 ratio to either early initiation of 3% hypertonic saline for 6 months or delayed initiation consisting of normal saline inhalation during the first 3 months followed by 3% hypertonic saline during the subsequent 3 months.\n\nThe primary objective is to compare respiratory symptom improvement between hypertonic saline and normal saline at Month 3. Secondary objectives include evaluating sputum microbiological outcomes, radiographic changes, inflammatory markers, small airway function, treatment initiation, safety, and within-participant changes before and after switching from normal saline to hypertonic saline in the delayed-initiation arm.\n\nThe first participant was enrolled on October 3, 2025.",[179,26],"Nontuberculous Mycobacterial Lung Disease",[181,182,179,26,183,184,185,186,187],"Hypertonic saline inhalation","Airway clearance therapy","Mycobacterium avium complex","Mycobacterium abscessus","Respiratory Severity Score","Nebulized Hypertonic Saline","NTM-LD","2026-06-10",{"date":156,"type":41},{"date":191,"type":41},"2025-10-03",{"date":193,"type":22},"2028-07-31",{"name":195,"class":196},"Taipei Veterans General Hospital, Taiwan","OTHER_GOV",{"id":198,"slug":199,"hasResults":12,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":16,"sex":17,"minAge":55,"maxAge":19,"enrollmentInfo":205,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":207,"conditions":208,"keywords":213,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":220,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":224,"locationsCount":47},"100642831","breathlessness-perceptions-within-respiratory-diseases-100642831","NCT07648082","Breathlessness Perceptions Within Respiratory Diseases","Exploring Differences in Breathlessness Perceptions Within Respiratory Diseases","BiRD","Inclusion Criteria:\n\n* • Aged 18 or over up to 100\n\n  * Known respiratory diagnosis\\* OR Healthy control\\*\\*\n  * Ongoing symptoms of breathlessness defined as ≥2 MRC dyspnoea scale\n  * Able to communicate in English\n  * Able to attend two study visits\n  * Able to provide written informed consent\n\n    * Known respiratory diagnosis could include, but is not limited to, COPD, Asthma, Bronchiectasis or ILD.\n    * Healthy controls are required to have an absence of a functionally limiting condition such as respiratory, cardiovascular, or musculoskeletal.\n\nExclusion Criteria:\n\n* • Unstable disease or undergoing investigations for unexplained symptoms\n\n  * Undergone a surgery within past six weeks\n  * Contraindications for exercise outlined by ACSM guidelines (Unstable CVD, hypertension etc)\n  * BMI ≥ 35kg\u002Fm2\n  * Unable to communicate in English\n  * Unable to provide written informed consent\n  * Unable to abstain from smoking for 8 hours prior to testing",{"count":206,"type":22},75,"Breathlessness is a complex symptom that results in poor quality of life, increased hospitalisations and increased mortality. Breathlessness is influenced by physiological, psychological and functional factors but these are poorly explored. There are also unexplored phenomenon's such as breathing pattern. Therefore, this study aims to understand the influences of physiology, psychology, function and breathing pattern on health related quality of life in those with a respiratory disease compared to healthy controls. This project is a cross-sectional cohort study including those with a known respiratory disease and experiencing breathlessness, compared to non-breathless healthy controls. The investigators will measure your physiology through spirometry (a breathing test that tells us about their lung function), psychology through questionnaires, function through an exercise test and breathing pattern using opto-electrictronic plethysmography (markers are placed on your chest to see how participants breathe while exercising). This will be conducted over two visits. The investigators will recruit participants from clinics at the University Hospitals of Leicester NHS Trust. The investigators are aiming to recruit 50 participants with a respiratory disease and 25 healthy controls. The results of this study will help us understand breathlessness in more detail in order to be able to develop better treatments.",[209,210,211,26,212],"Chronic Obstructive Pulmonary Disease (COPD)","Asthma (Diagnosis)","Interstitial Lung Disease (ILD)","Breathing Pattern Disorder",[214,215,216,217,218,219],"Breathlessness","OEP","Cardiopulmonary Exercise Testing","Respiratory diseases","Heart rate variability","Breathing patterns",{"date":156,"type":41},{"date":222,"type":41},"2025-06-06",{"date":70,"type":22},{"name":225,"class":165},"University Hospitals, Leicester",{"id":227,"slug":228,"hasResults":12,"nctId":229,"briefTitle":230,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":16,"sex":17,"minAge":232,"maxAge":4,"enrollmentInfo":233,"targetDuration":235,"studyType":23,"phases":4,"briefSummary":236,"conditions":237,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":4},"100643772","a-study-to-evaluate-the-diagnostic-performance-of-portable-oscillometry-across-chronic-respiratory-diseases-100643772","NCT07631507","A Study to Evaluate the Diagnostic Performance of Portable Oscillometry Across Chronic Respiratory Diseases","Inclusion Criteria:\n\n* COPD group:\n\n  * Age：≥40\n  * Suspected COPD：COPD-SQ≥16，and no evidence of airflow limitation after bronchodilators\n  * Confirmed COPD：According to the diagnostic criteria in the 2021 Revised Edition of the Chinese Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease and the 2026 GOLD Report, a diagnosis requires the presence of symptoms (such as dyspnea, chronic cough, or sputum production), a history of exposure to risk factors (e.g., smoking, biomass fuels, occupational exposures, or air pollution), evidence of persistent airflow limitation (post-bronchodilator FEV1\u002FFVC \\\u003C 0.70), and the exclusion of alternative diagnoses.\n  * Exclude acute exacerbation within the last month Asthma group：\n  * Age：≥3\n  * Suspected asthma：Patients with chronic respiratory symptoms but no evidence of variable airflow limitation\n  * Confirmed asthma：According to the diagnostic criteria in the 2024 Chinese Guidelines for the Prevention and Treatment of Bronchial Asthma and the 2025 GINA Report, diagnosis requires the presence of recurrent symptoms (such as wheezing, shortness of breath, chest tightness, and cough) that resolve spontaneously or with treatment; evidence of variable airflow limitation (e.g., a positive bronchodilator reversibility test, a positive bronchial provocation test, or an average daily diurnal PEF variability of \\>10% over at least 7 consecutive days); and the exclusion of alternative diagnoses.\n\nHealthy subjects:\n\n* Age ≥ 3 (See Table 1 for details)\n* No respiratory symptoms（cough, expectoration, shortness of breath, wheezing, etc）\n* No history of serious cardiopulmonary or other systemic diseases, especially no history of respiratory diseases and surgery\n* No history of respiratory infection within the past 4 weeks; non-smoker or total lifetime smoking \\\u003C 100 cigarettes\n* No history of occupational exposure to harmful gases or dust, or serious pollution of the work or living environment\n* No abnormalities on chest physical examination\n* No abnormalities were found on chest imaging (X-ray, CT) records within the past year.\n* Body mass index within the normal range (18.5\\~24.9) Confirmed Bronchiectasis Group：\n* Age ≥ 3 years\n* Clinical history consistent with bronchiectasis, confirmed by CT scan\n* No other concurrent or accompanying respiratory diseases at present Confirmed ILD Group：\n* Age ≥ 3 years\n* Fibrotic interstitial lung disease: HRCT scan shows fibrotic lung disease, defined as reticular abnormalities and traction bronchiectasis with or without honeycombing, and the disease extent \\> 10%; or lung tissue biopsy indicates fibrotic interstitial changes\n* No other concurrent or accompanying respiratory diseases at present Confirmed Upper Airway Obstruction Group：\n* Age ≥ 3 years, gender not restricted\n* History of upper airway inflammation, injury, endotracheal intubation or tracheotomy, burns, foreign body aspiration, tracheal tumor, or other conditions that can cause large airway obstruction\n* Clinical manifestations are mainly dyspnea and shortness of breath, which are significantly aggravated after activity, and sometimes symptom exacerbation is related to body position\n* Pulmonary function test shows significant limitation of inspiratory or expiratory flow in the F-V curve, presenting a characteristic plateau pattern\n* At least one of the following evidences: chest CT scan or upper airway three-dimensional reconstruction confirms upper airway stenosis; laryngoscopy or bronchoscopy reveals tracheal\u002Fbronchial wall thickening and\u002For stenosis, intratracheal nodules or neoplasms, tumor infiltration, tracheal mucosal congestion, tracheal cartilage collapse, etc\n\nExclusion Criteria:\n\n* • Contraindications for oscillometry testing and spirometry testing: Oscillometry testing: Severe and intolerable dyspnea, acute exacerbation of respiratory infection, uncontrolled epilepsy, oral or facial diseases or deformities preventing proper latching, tympanic membrane perforation, need for continuous oxygen therapy, indwelling gastric tube, tracheotomy with inability to close the tube, currently undergoing artificial ventilation and unable to temporarily stop the procedure; Spirometry testing: Recent severe cardiovascular disease, epileptic seizures, uncontrolled hypertension, aortic aneurysm, severe hyperthyroidism, heart rate \\>120 bpm, tympanic membrane perforation, other respiratory infectious diseases, etc.;\n\n  * Other respiratory diseases that affect lung function results： such as lung cancer, pneumonia, active pulmonary tuberculosis, pulmonary embolism, etc.; Recent surgical history that affects lung function results, including open-chest surgery, pleural effusion surgery, etc.;\n  * Poor cooperation during basic lung function tests, failing to meet quality control requirements;\n  * Breastfeeding women;\n  * Participants deemed unlikely by the researcher to comply with research procedures and restrictions.","3 Years",{"count":234,"type":22},4000,"1 Day","This is a prospective, multicenter, observational cohort study enrolling approximately 4,000 subjects across about 50 centers, including patients with COPD (confirmed and suspected), asthma (confirmed and suspected), bronchiectasis, interstitial lung disease (ILD), upper airway obstruction (UAO), and healthy controls. Participants will undergo standardized clinical assessments, cough search, FENO, ETCO2, impulse oscillometry, spirometry, and\u002For bronchodilator test, and\u002For bronchoprovocation test, and\u002For diffusion capacity test at a single baseline visit, with no investigational intervention or treatment assignment. The primary objective is to evaluate the diagnostic performance of portable impulse oscillometry in Chronic respiratory diseases and to develop an artificial intelligence diagnostic model for COPD based on oscillometry. The study duration per subject is limited to the screening\u002Fbaseline visit, with no follow-up visits planned.",[238,210,239,26,211,240],"COPD","Chronic Respiratory Diseases","Upper Airway Obstruction","2026-06-02",{"date":243,"type":41},"2026-06-08",{"date":245,"type":22},"2026-07-30",{"date":247,"type":22},"2027-08-30",{"name":249,"class":165},"The First Affiliated Hospital of Guangzhou Medical University",{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":59,"phases":259,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":47},"100614738","phase-4-itraconazole-therapy-in-bronchiectasis-with-airway-mold-100614738","NCT07283497","Itraconazole Therapy In Bronchiectasis With Airway Mold","Itraconazole Therapy In Bronchiectasis With Airway Mold: A Single-Arm Pilot Trial Of Feasibility, Safety, And Impact On Respiratory Symptoms And Airway Microbiome Diversity","Inclusion Criteria:\n\n* Age ≥18 years seen at Mycobacterial and Bronchiectasis Clinic (MMBC) in Rochester\n* Diagnosis of bronchiectasis confirmed by MMBC provider and chest CT\n* Within the last 3 months - culture growth of a mold in high quantity ('many') or culture growth of at least two distinct mold species in any quantity\n* Not actively on antimicrobial therapy AND no current plan to initiate antimicrobial therapy at the time of enrollment, as determined by treating provider\n* Ability to produce spontaneous sputum at Visit 1.\n\nExclusion Criteria:\n\n* Known diagnosis of allergic bronchopulmonary aspergillosis or invasive fungal disease\n* Use of the following medications: rifampin, rifabutin, phenobarbital, phenytoin, carbamazepine, dofetilide, quinidine, dronedarone, simvastatin, lovastatin, certain immunosuppressants (tacrolimus, cyclosporine, sirolimus, everolimus) and anticoagulants (rivaroxaban, apixaban, edoxaban, warfarin).\n* Abnormal baseline liver function tests (ALT, AST, alkaline phosphatase, or bilirubin \\> upper limit of normal)\n* Prolonged QTc interval on baseline ECG (\\>460 ms in females or \\>450 ms in males)\n* History of congestive heart failure (black box warning), known cardiomyopathy, or arrhythmias\n* Pregnancy or lactation\n* Known hypersensitivity or contraindication to azole antifungal therapy\n* Prior use of systemic antifungals within the past 3 months",{"count":258,"type":22},30,[260],"PHASE4","The primary objective of this study is to evaluate the feasibility of itraconazole therapy in patients with bronchiectasis and airway mold. Feasibility will be assessed through recruitment success, treatment adherence, tolerability, and participant retention. The study will also explore the impact on respiratory symptoms and airway microbiome diversity.",[26,263],"Fungal Infection of Upper Respiratory Tract","2026-05-27",{"date":266,"type":41},"2026-05-29",{"date":268,"type":22},"2026-06-20",{"date":270,"type":22},"2030-12-31",{"name":272,"class":165},"Mayo Clinic",{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":281,"targetDuration":4,"studyType":59,"phases":283,"briefSummary":284,"conditions":285,"keywords":289,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":47},"100638185","phase-4-azithromycin-to-modify-bronchiectasis-exacerbation-risk-100638185","NCT07608328","Azithromycin to Modify Bronchiectasis Exacerbation Risk","AMBER: Azithromycin to Modify Bronchiectasis Exacerbation Risk - A Double-Blind Placebo-Controlled Randomized Trial in Adults With Non-Cystic Fibrosis Bronchiectasis","AMBER","Inclusion Criteria:\n\n* Adult patients aged 18 years or older.\n* Clinically and radiologically confirmed non-cystic fibrosis bronchiectasis (NCFB).\n* Diagnosis supported by clinical assessment and high-resolution computed tomography (HRCT).\n* Patients attending outpatient clinics, inpatient wards, respiratory follow-up services, or routine bronchiectasis care pathways at Assiut University Hospitals during the enrollment period.\n* Suitable for baseline disease-signature assessment.\n* Able to undergo protocol-defined clinical, functional, radiological, oxygenation, inflammatory, symptom, and safety assessment.\n* Able to complete planned 12-month follow-up.\n* Eligible for randomization after baseline safety evaluation.\n* Written informed consent obtained from the participant or legal representative.\n\nExclusion Criteria:\n\n* Cystic fibrosis-related bronchiectasis.\n* Traction bronchiectasis due to advanced fibrotic interstitial lung disease as the dominant respiratory diagnosis.\n* Active pulmonary tuberculosis at enrollment.\n* Active nontuberculous mycobacterial pulmonary disease requiring specific treatment at enrollment.\n* Active malignancy or terminal non-respiratory illness expected to prevent planned follow-up.\n* Acute life-threatening illness preventing safe enrollment, baseline assessment, or randomization.\n* Recent major thoracic surgery or acute thoracic trauma interfering with baseline respiratory assessment.\n* Known hypersensitivity, contraindication, or serious intolerance to azithromycin or macrolide therapy.\n* Baseline cardiac findings judged by the investigator to make long-term azithromycin unsafe.\n* Requirement for long-term maintenance macrolide therapy at enrollment.\n* Current long-term maintenance macrolide use that cannot be safely discontinued before enrollment.\n* Inability to complete required baseline disease-signature assessment.\n* Inability or unwillingness to complete planned 12-month follow-up.\n* Refusal to participate.",{"count":282,"type":22},500,[260],"The Azithromycin to Modify Bronchiectasis Exacerbation Risk (AMBER) trial is a prospective, randomized, double-blind, placebo-controlled, parallel-group clinical trial in adults with clinically and radiologically confirmed non-cystic fibrosis bronchiectasis (NCFB).\n\nThe trial evaluates whether azithromycin 250 mg orally once daily for 12 months, added to standard bronchiectasis care, reduces the occurrence of at least one bronchiectasis exacerbation during 12-month follow-up compared with matching placebo added to standard bronchiectasis care.\n\nParticipants will be randomized in a 1:1 allocation ratio to standard care plus matching placebo or standard care plus azithromycin. The primary analysis will follow the intention-to-treat (ITT) principle.\n\nThe AMBER trial is embedded within the Assiut University bronchiectasis translational research platform and is linked to the Bronchiectasis Assessment of Severity and Exacerbations (BASE) framework and the Bronchiectasis Phenotype Identification Model (BPIM). BASE and BPIM are not used for randomization stratification and will not modify the primary randomized comparison.\n\nThe locked Version 1.0 methodological disclosure document, protocol, and statistical analysis plan (SAP), primary sample-size source code, and endpoint-level sample-size support matrix are archived in Zenodo: https:\u002F\u002Fdoi.org\u002F10.5281\u002Fzenodo.20178963.\n\nThe AMBER public preregistration is also available through the Open Science Framework (OSF) under Digital Object Identifier (DOI) 10.17605\u002FOSF.IO\u002FRE54V.",[286,287,26,288],"Non-cystic Fibrosis Bronchiectasis","Bronchiectasis Adult","Bronchiectasis With Acute Exacerbation",[290,26,291,292,293,294,295,296,297,298],"Non-cystic fibrosis bronchiectasis (NCFB)","Bronchiectasis exacerbation","Exacerbation risk","azithromycin","macrolide therapy","double-blind placebo-controlled trial","randomized controlled trial (RCT)","12-month follow-up","Assiut University","2026-05-19",{"date":264,"type":41},{"date":302,"type":22},"2026-05-21",{"date":304,"type":22},"2027-06-30",{"name":298,"class":165},{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":316,"conditions":317,"keywords":318,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":47},"100638565","base-bronchiectasis-severity-and-exacerbation-risk-study-100638565","NCT07599839","BASE: Bronchiectasis Severity and Exacerbation Risk Study","BASE: Bronchiectasis Assessment of Severity and Exacerbations for Baseline Severity Classification and One-Year Exacerbation Risk Prediction in Non-Cystic Fibrosis Bronchiectasis","BASE","Inclusion Criteria:\n\n* Adult patients aged 18 years or older.\n* Diagnosis of non-cystic fibrosis bronchiectasis (NCFB) based on clinical assessment and high-resolution computed tomography (HRCT).\n* Clinically stable or routinely assessed patients with non-cystic fibrosis bronchiectasis (NCFB) eligible for baseline severity and risk assessment.\n* Patients attending outpatient clinic, inpatient ward, or respiratory follow-up services at Assiut University Hospitals during the study enrollment period.\n* Patients suitable for prospective baseline assessment using the Bronchiectasis Assessment of Severity and Exacerbations (BASE) framework.\n* Ability to undergo routine clinical, functional, radiological, oxygenation, and inflammatory assessment according to the study protocol.\n* Ability to complete planned 12-month follow-up for bronchiectasis exacerbation and outcome assessment.\n* Written informed consent obtained from the patient or legal representative.\n\nExclusion Criteria:\n\n* Cystic fibrosis-related bronchiectasis.\n* Traction bronchiectasis due to advanced fibrotic interstitial lung disease as the dominant respiratory diagnosis.\n* Active pulmonary tuberculosis at enrollment.\n* Active nontuberculous mycobacterial pulmonary disease requiring specific treatment at enrollment.\n* Active malignancy or terminal non-respiratory illness expected to prevent 12-month follow-up.\n* Acute life-threatening illness preventing safe enrollment or baseline assessment.\n* Recent major thoracic surgery or acute thoracic trauma interfering with baseline respiratory assessment.\n* Inability to complete the required baseline or Bronchiectasis Assessment of Severity and Exacerbations (BASE) assessment according to the study protocol.\n* Inability or unwillingness to complete planned 12-month follow-up.\n* Refusal to participate.",{"count":315,"type":22},750,"Non-cystic fibrosis bronchiectasis (NCFB) is a chronic airway disease characterized by permanent bronchial dilatation, impaired mucus clearance, recurrent infection, airway inflammation, and repeated exacerbations. Existing bronchiectasis severity tools are clinically useful, but many depend on prior exacerbation history, hospitalization history, subjective symptom assessment, or culture-based microbiological classification.\n\nThis prospective observational cohort study aims to develop and validate the Bronchiectasis Assessment of Severity and Exacerbations (BASE) framework. BASE is designed to classify current bronchiectasis severity and predict 12-month exacerbation risk using objective baseline functional, radiological, oxygenation, and inflammatory variables. Detailed methodological specifications, including variable definitions, scoring architecture, endpoint hierarchy, development-validation governance, and analytical integrity rules, are archived in a restricted-access Zenodo record: https:\u002F\u002Fdoi.org\u002F10.5281\u002Fzenodo.20143505\n\n.\n\nParticipants will receive routine clinical care, and no treatment or intervention will be assigned by the study protocol. Patients will be followed for 12 months to record bronchiectasis exacerbations, hospitalization, lung-function change, inflammatory marker change, and clinical outcomes. The Bronchiectasis Assessment of Severity and Exacerbations (BASE) framework includes two linked baseline models: the BASE Severity model (BASE-S) for current bronchiectasis severity classification and the BASE Prognostic model (BASE-P) for prediction of 12-month exacerbation risk. Both models will be derived in the development cohort and applied unchanged to the validation cohort.",[26,286,288],[290,26,319,291,292,320,321,322,323],"Bronchiectasis severity","One-year exacerbation risk","Baseline risk prediction","Disease-signature model","Prospective observational cohort","2026-05-15",{"date":326,"type":41},"2026-05-20",{"date":328,"type":41},"2025-09-11",{"date":330,"type":22},"2027-02-01",{"name":298,"class":165},{"id":333,"slug":334,"hasResults":12,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":338,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":340,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":341,"conditions":342,"keywords":343,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":348,"startDateStruct":349,"completionDateStruct":350,"leadSponsor":352,"locationsCount":47},"100639767","bronchiectasis-phenotype-identification-model-100639767","NCT07599969","Bronchiectasis Phenotype Identification Model","BPIM: Bronchiectasis Phenotype Identification Model for Supervised Baseline Translation of Latent Class Trajectory Analysis-Derived Phenotypes in Non-Cystic Fibrosis Bronchiectasis","BPIM","Inclusion Criteria:\n\n* Adult patients aged 18 years or older.\n* Diagnosis of non-cystic fibrosis bronchiectasis (NCFB) based on clinical assessment and high-resolution computed tomography (HRCT).\n* Patients attending outpatient clinics, inpatient wards, or respiratory follow-up services at Assiut University Hospitals during the study enrollment period.\n* Patients suitable for baseline disease-signature assessment within the Bronchiectasis Phenotype Identification Model (BPIM) framework.\n* Ability to undergo routine clinical, functional, radiological, oxygenation, and inflammatory assessment according to the study protocol.\n* Ability to complete planned longitudinal follow-up required for latent class trajectory analysis (LCTA) and Bronchiectasis Phenotype Identification Model (BPIM) validation.\n* Written informed consent obtained from the patient or legal representative.\n\nExclusion Criteria:\n\n* Cystic fibrosis-related bronchiectasis.\n* Traction bronchiectasis due to advanced fibrotic interstitial lung disease as the dominant respiratory diagnosis.\n* Active pulmonary tuberculosis at enrollment.\n* Active nontuberculous mycobacterial pulmonary disease requiring specific treatment at enrollment.\n* Active malignancy or terminal non-respiratory illness expected to prevent planned follow-up.\n* Acute life-threatening illness preventing safe enrollment or reliable baseline assessment.\n* Recent major thoracic surgery or acute thoracic trauma interfering with baseline respiratory assessment.\n* Inability to complete required baseline disease-signature assessment according to the Bronchiectasis Phenotype Identification Model (BPIM) protocol.\n* Inability or unwillingness to complete planned longitudinal follow-up.\n* Refusal to participate.",{"count":315,"type":22},"The Bronchiectasis Phenotype Identification Model (BPIM) is a prospective observational development-validation study within the Assiut University bronchiectasis translational research platform.\n\nThe study evaluates whether latent class trajectory analysis (LCTA)-derived bronchiectasis phenotype classes can be translated into a supervised baseline classifier for adults with non-cystic fibrosis bronchiectasis (NCFB).\n\nLatent class trajectory analysis (LCTA) will first identify trajectory-derived phenotype classes using prospectively collected longitudinal disease-signature data. The Bronchiectasis Phenotype Identification Model (BPIM) will then be trained to predict the accepted latent class trajectory analysis (LCTA)-derived phenotype class using the locked baseline disease-signature architecture.\n\nThis study is observational and non-interventional. No treatment, medication, intervention, exposure, or management strategy is assigned by the protocol. All participants receive routine clinical care according to institutional practice and treating physician judgment.\n\nThe locked methodological disclosure, protocol, and deterministic statistical analysis plan are archived in the version-specific Zenodo record: https:\u002F\u002Fdoi.org\u002F10.5281\u002Fzenodo.20157926.",[26,286,288],[290,26,344,291,292,320,321,322,323,345,346,347],"Bronchiectasis Phenotype Identification Model (BPIM)","Development-validation study","Latent class trajectory analysis (LCTA)","supervised phenotype classifier",{"date":326,"type":41},{"date":328,"type":41},{"date":351,"type":22},"2026-12-01",{"name":298,"class":165},{"id":354,"slug":355,"hasResults":12,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":360,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":362,"conditions":363,"keywords":365,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":47},"100607757","health-impact-of-non-tuberculous-mycobacteria-pulmonary-disease-ntm-pd-100607757","NCT07192705","Health Impact of Non-Tuberculous Mycobacteria Pulmonary Disease (NTM-PD)","An Observational Cross-sectional Study Exploring Differences in Health Between People With Non-Tuberculous Mycobacteria Pulmonary Disease and People With Bronchiectasis Without NTM Pulmonary Infection.","Inclusion Criteria:\n\n\\- Age: 18 years or older, able to provide informed consent.\n\nNTM-PD Group:\n\n* Participants will be adults diagnosed with confirmed NTM-PD based on the British Thoracic Society (BTS) guidelines.\n* The participant should not be on any antimicrobial therapy (at least two weeks before participation) and should not have previously received or be currently on antimicrobial therapy for NTM-PD.\n\n  \\* BTS guidelines:\n* Clinical (both required):\n* Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or a high-resolution CT scan that shows multifocal bronchiectasis with multiple small nodules.\n* Appropriate exclusion of other diagnoses.\n* Microbiological:\n* A minimum of two positive expectorated sputum culture results of the same NTM species from samples collected on separate days within 12 months before recruitment.\n\nOR\n\n* Positive culture results from at least one bronchial wash or lavage. OR\n* Transbronchial or other lung biopsy with mycobacterial histopathological features (granulomatous inflammation or AFB) and positive culture for NTM or biopsy showing mycobacterial histopathological features (granulomatous inflammation or AFB) and one or more sputum or bronchial washings that are culture-positive for NTM.\n\nBronchiectasis Group:\n\n* Diagnosed with bronchiectasis, as confirmed in medical records based on clinical assessment, and radiological findings.\n* Never had a history of positive culture result for NTM pulmonary infection.\n* The latest NTM-negative result must be within the past 12 months from the study's start date or no earlier than 2024.\n\nExclusion Criteria:\n\n\\- Age: Under 18 years of age, or unable to provide informed consent.\n\nNTM-PD Group:\n\n* No confirmation of NTM-PD diagnosis.\n* Diagnosed with a reinfection of NTM-PD.\n* Started antimicrobial therapy for NTM-PD.\n\nBronchiectasis Group:\n\n* No diagnosis of bronchiectasis or diagnosis of bronchiectasis with NTM-PD.\n* Diagnosed with other chronic respiratory diseases considered primary conditions, rather than bronchiectasis.\n* Participants with a history of NTM pulmonary infection.\n* NTM-negative results obtained before 2024.",{"count":361,"type":22},80,"Nontuberculous mycobacteria (NTM) are environmental organisms found in soil and water. The majority do not cause human disease. When they do, this is mostly as a chronic lung infection in people with long-term lung problems such as chronic obstructive pulmonary disease (COPD), bronchiectasis, or cystic fibrosis. The number of people with NTM pulmonary disease (PD) is increasing, and its management can be complex, requiring prolonged treatment with multiple, often toxic, drugs in someone who may already be frail.\n\nNon-drug approaches, such as airway clearance techniques, structured exercise, nutritional support and psychological care are used to help manage bronchiectasis and COPD. However, there is limited evidence about their benefit in people with NTM-PD. Also, it is not clear whether these patients' health needs are different from people with bronchiectasis alone.\n\nThe investigators want to identify the most important symptoms encountered by people with NTM-PD and patient preferences for care. The study also aims to explore whether the need for non-drug measures differs between people with and without NTM-PD who have other underlying lung disease.\n\nThe research will take place at one NHS centre and involve a single assessment of 40 people with NTM-PD not using specific antibiotics to treat their NTM and 40 people with bronchiectasis but no evidence for NTM. Following consent, and mainly using questionnaires, participants will be asked about their physical and mental health, and nutritional status. Exercise capacity, muscle strength and body muscle\u002Ffat composition will also be assessed using simple tests. The total time required will be a maximum of one hour. Recruitment to the study will last around six months.\n\nThe results will help improve understanding of specific needs of people with NTM-PD and guide clinically relevant research in this area.",[364,26],"Non-Tuberculous Mycobacteria Pulmonary Disease",[364,366,367,368,26,187,369,370],"NTM-PD","Non-Tuberculous Mycobacteria Lung Disease","Health Impact of NTM-PD","Bronchiectasis without NTM-PD","Non-Pharmacological Intervention","2026-05-13",{"date":373,"type":41},"2026-05-14",{"date":375,"type":41},"2025-08-14",{"date":377,"type":22},"2026-06-01",{"name":379,"class":165},"University College, London",{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":387,"enrollmentInfo":388,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":389,"conditions":390,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":47},"100499485","study-of-bronchiectasis-and-associated-cardiovascular-comorbidities-100499485","NCT05783869","Study of Bronchiectasis and Associated Cardiovascular Comorbidities","Effect of Cardiovascular Comorbidities on Disease Severity and Quality of Life in Patients With Acute Exacerbation of Non-cystic Fibrosis Bronchiectasis","Inclusion Criteria:\n\n• Any Patients with Bronchiectasis had no comorbidities other than cardiovascular comorbidities during the study period.\n\nExclusion Criteria:\n\n* Any Patients who refuse to participate in the study.\n* Any other comorbidity or end-organ failure may affect the study's result.","80 Years",{"count":258,"type":22},"Effect of cardiovascular comorbidities on disease severity and quality of life in Patients with acute exacerbation of non-cystic fibrosis bronchiectasis",[26],"2026-05-11",{"date":371,"type":41},{"date":394,"type":41},"2023-03-25",{"date":396,"type":22},"2026-11-02",{"name":298,"class":165},{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":16,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":407,"conditions":408,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":47},"100591664","validation-and-clinical-utility-of-the-lung-sliding-index-lsi-for-differentiating-pulmonary-diseases-100591664","NCT06983366","Validation and Clinical Utility of the Lung Sliding Index (LSI) for Differentiating Pulmonary Diseases","Validation and Clinical Utility of the Lung Sliding Index (LSI) for Differentiating Pulmonary Diseases: A Prospective Case-Control Study","Inclusion Criteria:\n\n* Age 18 years and older.\n* Diagnosed with one of the specified pulmonary diseases, or a healthy control\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Inability to tolerate or undergo a lung ultrasound\n* Extensive chest wall pathology precluding assessment\n* Unscorable \\>2 zones per protocol\n* Withdrawal of consent\n* Mechanically-ventilated patients",{"count":406,"type":22},700,"This upcoming case-control study aims to confirm the Lung Sliding Index (LSI), a new ultrasound score that measures how well the pleura moves, in various lung diseases. The study will check how well the LSI can tell apart different lung diseases (like pneumothorax, interstitial lung disease, COPD, pneumonia, and pulmonary edema), how it relates to signs of disease severity, and how consistent the results are between different operators who have received the same training. Secondary objectives include assessing patient and operator satisfaction and feasibility using validated Likert scales.",[238,409,26,410,411,412,413],"ILD","Pneumothorax","Pneumonia","Pleural Effusion Disorder","Pulmonary Oedema","2026-04-26",{"date":416,"type":41},"2026-04-30",{"date":418,"type":41},"2025-05-30",{"date":420,"type":22},"2026-08-01",{"name":298,"class":165},{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":387,"enrollmentInfo":429,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":431,"conditions":432,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":433,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":437,"locationsCount":47},"100496243","hfnc-in-management-of-bronchiectasis-exacerbation-100496243","NCT05741697","HFNC in Management of Bronchiectasis Exacerbation","High Flow Nasal Cannula Versus Non-invasive Ventilation in Managing Acute Exacerbation of Bronchiectasis Patients","Inclusion Criteria:\n\n* Patients will be eligible for enrolment if diagnosed with bronchiectasis and admitted to the respiratory intensive care unit (RICU), requiring ventilator support without invasive mechanical ventilation.\n\nExclusion Criteria:\n\n* Age: less than 18 years. Patients with post-arrest encephalopathy. Patient with the previous tracheotomy. Patients who received invasive ventilatory support. Patients with end-organ failure.",{"count":430,"type":22},20,"Patients with Bronchiectasis experience exacerbations with hypercapnic respiratory failure associated with an increased respiratory workload that may require intensive care unit (ICU) admission due to the inability of the respiratory muscles to compensate for increased demand. These exacerbations are frequently treated with noninvasive ventilation (NIV).",[26],{"date":416,"type":41},{"date":435,"type":41},"2023-03-01",{"date":160,"type":22},{"name":298,"class":165},{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":4,"eligibilityCriteria":444,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":445,"targetDuration":4,"studyType":59,"phases":446,"briefSummary":447,"conditions":448,"keywords":450,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":47},"100634429","telerehabilitation-in-patients-with-bronchiectasis-100634429","NCT07539571","Telerehabilitation in Patients With Bronchiectasis","Effectiveness of a 12-week Telerehabilitation Training in Patients With Bronchiectasis: A Randomized Controlled Trial.","Inclusion Criteria:\n\n* Bronchiectasis diagnosed by high resolution computed tomography (HRCT) of the chest.\n* Clinically stable patients (without hospitalizations, infection or changes in pharmacological treatment in the last month of the study beginning).\n* Both gender\n* Non smokers.\n* Internet connection available.\n\nExclusion Criteria:\n\n* Inability to give informed consent to participate\n* Less of 18 years\n* With other lung related diseases (asthma, COPD and cystic fibrosis)\n* Decompensated cardiovascular and metabolic diseases, neuromuscular or musculoskeletal that impede the realization of the protocol.\n* Mental disorders that prevent the adequate participation in the tele-rehabilitation program.\n* Simultaneous participation in another clinical trial.",{"count":361,"type":22},[148],"Background: Home-based telerehabilitation (TR) has demonstrated benefits comparable to conventional rehabilitation in patients with chronic obstructive pulmonary disease, asthma, and pulmonary fibrosis. However, TR has not been thoroughly investigated in patients with bronchiectasis, despite evidence suggesting improvements in exercise capacity and quality of life.\n\nAims: To evaluate the effects of TR on functional capacity, quality of life, and inflammatory biomarkers, as well as its safety in patients with bronchiectasis.\n\nStudy design: Single-center randomized controlled trial with a parallel-group design.\n\nMethods: Patients diagnosed with bronchiectasis will be recruited from the Surgical Medical Unit for Respiratory Diseases at Virgen del Rocío University Hospital. Participants will be randomly assigned to one of two groups: a control group receiving usual care, and a TR group undergoing supervised physical training for 12 weeks, three times per week. Outcome measures will include the 6-minute walk test, quality-of-life questionnaires, pulmonary function tests, symptom assessment, and adverse event recording, as well as sputum microbiology and analysis of inflammatory biomarkers. Assessments will be conducted at baseline and at the end of the intervention.\n\nExpected results: A 12-week TR program is expected to significantly improve exercise capacity and quality of life in the intervention group. Additionally, this study may contribute to the development of future clinical guidelines regarding the use of TR in patients with bronchiectasis.",[26,449],"Telerehabilitation",[26,449,451,452],"Quality of life","Inflammation","2026-04-16",{"date":455,"type":41},"2026-04-20",{"date":457,"type":22},"2026-09",{"date":459,"type":22},"2032-12",{"name":461,"class":165},"Hospitales Universitarios Virgen del Rocío",{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":4,"eligibilityCriteria":468,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":59,"phases":471,"briefSummary":472,"conditions":473,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":476,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":484},"100587322","ole-therapy-with-be-patients-in-home-care-study-100587322","NCT06926881","OLE Therapy With BE Patients in Home Care Study","Oscillating Lung Expansion (OLE) Therapy in the Bronchiectasis Patients (BE) Home Care Study Protocol","Inclusion Criteria\n\nTo be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Patients aged \\> 5 years old.\n2. History of one or more respiratory exacerbations in the past 6 months or two or more respiratory exacerbations in the past 12 months, which required unplanned or unscheduled medical intervention.\n3. Ability to perform BiWaze Clear therapy as prescribed.\n4. Clinically stable respiratory status at the time of screening.\n5. Bronchiectasis diagnosis (including patients with cystic fibrosis with documented bronchiectasis).\n6. Signed informed consent (and Child assent if minor subject).\n\nExclusion Criteria\n\nAn individual who meets any of the following criteria will be excluded from participating in this study:\n\n1. Diagnosis with rapidly progressing NMD.\n2. Anticipated requirement for hospitalization within the next six months.\n3. History of pneumothorax within the past 6 months.\n4. Use of OLE therapy within the past 12 months.\n5. Inability or unwillingness to perform OLE therapy or study procedures as required.\n6. Currently enrolled in a different study.\n7. Current smoker or tobacco use within the last 30 days.\n8. Pregnancy or Breastfeeding.\n9. Any medical conditions deemed by investigators to have a significant impact on the study results, e.g., active cancer, severe cardiovascular, severe progressive pulmonary disease, liver, kidney, or neurological conditions.\n10. Inability to comply with the treatment protocol or study procedures.\n11. Known allergies to materials used in OLE device.",{"count":470,"type":22},85,[148],"The study will examine how the performance of Oscillating Lung Expansion (OLE) therapy affects the respiratory health of patients with Bronchiectasis (BE).\n\nThe patient will use the BiWaze Clear system for their airway clearance therapy, instead of their previously prescribed therapy. BiWaze Clear is an FDA-cleared respiratory therapy for assisting patients in loosening and mobilizing secretions as well as treating and preventing atelectasis by providing lung expansion and high-frequency oscillation therapies, combined with aerosol delivery.\n\nThe patient will perform airway clearance with BiWaze Clear as prescribed. The system uses a disposable breathing circuit, which is a single patient use, disposable circuit.\n\nThe treatment duration is 6 months . The BiWaze Clear System is indicated for the mobilization of secretions, lung expansion therapy, the treatment and prevention of pulmonary atelectasis and has the ability to provide supplemental oxygen when used with an oxygen supply.",[26,474],"Pulmonary Exacerbation","2026-04-09",{"date":477,"type":41},"2026-04-14",{"date":479,"type":41},"2025-05-20",{"date":481,"type":22},"2026-08-31",{"name":483,"class":165},"Delve Health",5,{"id":486,"slug":487,"hasResults":12,"nctId":488,"briefTitle":489,"officialTitle":490,"acronym":4,"eligibilityCriteria":491,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":492,"enrollmentInfo":493,"targetDuration":4,"studyType":59,"phases":494,"briefSummary":495,"conditions":496,"keywords":497,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":511},"100633167","phase-2-efficacy-and-safety-of-lifei-qingchang-granules-for-stable-bronchiectasis-100633167","NCT07523165","Efficacy and Safety of Lifei Qingchang Granules for Stable Bronchiectasis","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study on the Efficacy and Safety of Lifei Qingchang Granules for Stable Bronchiectasis","Inclusion Criteria:\n\n* Aged 18 to 75 years old, regardless of sex.\n* Diagnosed with bronchiectasis confirmed by High-Resolution Computed Tomography (HRCT) scan.\n* Bronchiectasis is currently in the stable phase.\n* Experienced at least one acute exacerbation of bronchiectasis within the previous 12 months.\n* Diagnosed with the Traditional Chinese Medicine (TCM) syndrome of \"Phlegm-Heat Obstructing the Lungs\".\n* Able to understand the study protocol and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Allergic to any ingredients of the investigational drug or placebo.\n* Comorbid with other severe systemic diseases (e.g., coronary heart disease, stroke, severe hypertension \\[systolic BP ≥ 180 mmHg or diastolic BP ≥ 110 mmHg\\], active gastric ulcer, uncontrolled diabetes \\[fasting venous blood glucose ≥ 10 mmol\u002FL\\], malignant tumors, abnormal liver or kidney function \\[AST, ALT, or GGT \\> 2 times the upper limit of normal; or serum creatinine \\> 2 times the upper limit of normal\\]) or psychiatric disorders.\n* Comorbid with asthma, allergic bronchopulmonary aspergillosis (ABPA), or active pulmonary tuberculosis.\n* Comorbid with chronic obstructive pulmonary disease (COPD) and presenting COPD as the primary clinical manifestation (as judged by the investigator).\n* Use of inhaled, oral, or intravenous antibiotics within 4 weeks prior to enrollment.\n* Type 2 respiratory failure requiring long-term non-invasive mechanical ventilation or oxygen therapy (\\> 10 hours\u002Fday).\n* History of drug abuse, psychotropic drug dependence, or alcohol abuse.\n* Current smokers or those unable to stop smoking during the study.\n* Pregnant or lactating women, planning to become pregnant during the study, or refusing to use reliable contraceptive methods throughout the study period.\n* Participation in any other clinical trials within 3 months prior to enrollment.\n* Considered unsuitable for participation in this clinical study by the investigator.","75 Years",{"count":146,"type":22},[61],"The purpose of this study is to evaluate the efficacy and safety of Lifei Qingchang Granules in the treatment of patients with stable bronchiectasis. This is a multicenter, randomized, double-blind, placebo-controlled clinical trial.\n\nResearchers plan to enroll a total of 150 adult participants (aged 18-75) who have been diagnosed with stable bronchiectasis and experience at least one acute exacerbation in the past 12 months. Participants will be randomly assigned into two groups in a 1:1 ratio:\n\n* The treatment group will receive Lifei Qingchang Granules along with standard postural drainage therapy.\n* The control group will receive a matching placebo along with standard postural drainage therapy.\n\nThe treatment period will last for 3 months. The main goal is to see if the treatment can improve patients' respiratory symptoms and overall quality of life.",[26],[498,499,500,501,502],"Stable Bronchiectasis","Traditional Chinese Medicine","Phlegm-Heat Syndrome","Lifei Qingchang Granules","Postural Drainage","2026-04-04",{"date":505,"type":41},"2026-04-13",{"date":507,"type":22},"2026-04",{"date":509,"type":22},"2028-04",{"name":249,"class":165},3,{"id":513,"slug":514,"hasResults":12,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":518,"eligibilityCriteria":519,"healthyVolunteers":16,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":520,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":522,"conditions":523,"keywords":527,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":539,"locationsCount":47},"100630896","immune-status-and-disease-control-of-inflammatory-airway-diseases-100630896","NCT07493629","Immune Status and Disease Control of Inflammatory Airway Diseases","Association Between Immune Status and Disease Control in Patients With Inflammatory Airway Diseases","ISDC-IAD","Inclusion Criteria\n\n1. Age ≥18 years (≥40 years for COPD patients).\n2. Clinical diagnosis of asthma, ABPA, bronchiectasis, OSAS, or COPD according to established criteria.\n3. PRISm patients (post-BD FEV1\u002FFVC ≥70% and FEV1 \\\u003C80% predicted)\n4. Smoking controls: ≥10 pack-years, normal lung function, no chronic respiratory symptoms.\n5. Healthy controls: normal lung function, FeNO \\\u003C20 ppb, total IgE \\\u003C100 IU\u002FmL, no chronic disease, smoking \\\u003C10 pack-years, no immunosuppressant use within 3 months.\n\nExclusion Criteria\n\n1. Patients with severe respiratory diseases other than those included in the study, such as pulmonary embolism, pneumothorax, pulmonary hypertension, interstitial lung disease, or active lung cancer.\n2. Patients with severe systemic diseases that may interfere with study completion, such as myocardial infarction, severe arrhythmia, hepatic insufficiency, renal insufficiency, hematological disorders, or malignancy.\n3. Patients with an acute exacerbation within 4 weeks before enrollment, or systemic use of antibiotics, antifungal drugs, immunosuppressive agents, cytotoxic agents, or corticosteroids (except for long-term maintenance therapy)\n4. Pregnant or lactating women.\n5. Patients with poor compliance as judged by the investigators.\n6. Subjects currently participating in other clinical studies.",{"count":521,"type":22},200,"The goal of this study is to learn how the body's immune system affects disease control in people with different airway inflammatory diseases.We want to understand:\n\n1.Whether specific immune cell patterns in the blood are linked to how severe the disease is or how well it is controlled.\n\nParticipants will:\n\n1. Answer questions about their health and symptoms.\n2. Give blood samples\n3. Have lung function tests and other standard check-ups.\n4. share sleep study results. We will compare people with airway diseases to healthy volunteers to see how their immune systems differ.",[524,209,210,26,525,526],"Airway Inflammation","OSAS (Obstructive Sleep Apneas Syndrome)","Allergic Bronchopulmonary Aspergillosis (ABPA)",[528,529,530,531,532],"Airway Inflammatory Diseases","Immunophenotyping","Metabolomics","Cytometry by Time-of-Flight","High-dimensional immune profiling","2026-03-23",{"date":535,"type":41},"2026-03-25",{"date":537,"type":41},"2025-08-01",{"date":420,"type":22},{"name":540,"class":541},"First Affiliated Hospital of Ningbo University","NETWORK",{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":547,"acronym":4,"eligibilityCriteria":548,"healthyVolunteers":16,"sex":17,"minAge":55,"maxAge":387,"enrollmentInfo":549,"targetDuration":4,"studyType":59,"phases":550,"briefSummary":552,"conditions":553,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":562},"100528844","phase-1-a-study-to-investigate-the-safety-tolerability-and-pharmacokinetics-of-inhaled-chf6333-after-single-doses-in-healthy-volunteers-and-after-single-and-repeated-doses-in-subjects-with-bronchiectasis-100528844","NCT06166056","A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis","A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Ascending Doses in Healthy Volunteers and One Single Dose in Adult Subjects With Bronchiectasis, Followed by a Placebo-controlled, Repeated Dose, 3-way Cross-over in Adult Subjects With Bronchiectasis","HV Inclusion Criteria:\n\n1. Signed and dated informed consent obtained prior to any study-related procedure;\n2. Healthy male or female subject ≥18 and ≤60 years of age at screening;\n3. Ability to understand the study procedures and the risks involved, and to be trained to use inhalers correctly and to generate sufficient peak inspiratory flow (PIF) (at least 40 L\u002Fmin) using the In-Check Dial set as per \"GenuAir\" inhaler resistance, at screening;\n4. Body mass index (BMI) ≥18 and ≤35 kg\u002Fm2 at screening;\n5. Non-smokers or ex-smokers who smoked \\\u003C5 pack-years and stopped smoking \\>1 year prior to screening;\n6. Good physical and mental status, determined via assessment of medical history and clinical examination, at screening and prior to randomisation;\n7. Vital signs within normal limits at screening and prior to randomisation: diastolic blood pressure (DBP) ≥40 and ≤89 mmHg, and systolic blood pressure (SBP) ≥90 and ≤139 mmHg; body temperature \\\u003C37.5°C;\n8. Triplicate 12-lead electrocardiogram (ECG) considered as normal (40 ≤ heart rate ≤110 bpm, 120 ms ≤ PR ≤210 ms, QRS ≤120 ms, Fridericia corrected QT interval \\[QTcF\\] ≤450 ms for males and QTcF ≤470 ms for females) at screening and prior to randomisation;\n9. Lung function measurements within limits at screening and prior to randomisation: forced expiratory volume in 1 second (FEV1) \\>80% predicted and FEV1\u002Fforced vital capacity (FVC) ratio \\>0.70;\n10. Male subjects willing to use a male condom throughout the study if they have women of childbearing potential (WOCBP) partners; male subjects with non-WOCBP partners or who are sterile do not have contraception requirements;\n11. Female subjects (if WOCBP) and\u002For their partners (if fertile) must be willing to use a highly effective birth control method, preferably with low user dependency, throughout the study; female subjects who are non-WOCBP or who have non-fertile partners do not have contraception requirements.\n\nHV Exclusion Criteria:\n\n1. Participation in another clinical study where investigational drug was received and the last investigations were performed less than 3 months prior to randomisation;\n2. Clinically relevant and uncontrolled respiratory, cardiac, hepatic, gastrointestinal, renal, endocrine, hematologic, metabolic, neurological, or psychiatric disorders that may interfere with successful completion of this protocol, according to the investigator's judgment;\n3. Clinically relevant abnormal laboratory values at screening suggesting an unknown disease and requiring further clinical investigation or which may impact the safety of the subject or the evaluation of the results of the study, according to the investigator's judgment;\n4. History of respiratory diseases;\n5. Positive human immunodeficiency virus (HIV) 1 or HIV2 serology results at screening;\n6. Hepatitis serology results which indicate acute or chronic hepatitis B (HB) or hepatitis C virus (HCV) at screening;\n7. Documented coronavirus disease 2019 (COVID-19) diagnosis within 2 weeks prior to screening or prior to randomisation, or associated complications\u002Fsymptoms, which have not resolved within 2 weeks prior to screening;\n8. Blood donation or blood loss (equal or more than 450 mL) less than 2 months prior to screening or prior to randomisation;\n9. Abnormal liver enzymes at screening or prior to randomisation (alanine aminotransferase \\[ALT\\] or aspartate aminotransferase \\[AST\\] or bilirubin: \\>1.5× upper limit of normal \\[ULN\\]);\n10. Positive urine test for cotinine at screening or prior to randomisation;\n11. Documented history of alcohol abuse within 12 months prior to screening or a positive alcohol breath test at screening or prior to randomisation;\n12. Documented history of drug abuse within 12 months prior to screening or a positive urine drug screen at screening or prior to randomisation;\n13. Treatment with prohibited concomitant medications or if the subject is expected to take prohibited concomitant medications during the study;\n14. Presence of any current infection, or previous infection that resolved less than 7 days prior to screening or prior to randomisation;\n15. Known intolerance and\u002For hypersensitivity to any of the excipients contained in the formulation used in the study;\n16. Unsuitable veins for repeated venepuncture;\n17. Heavy caffeine drinker;\n18. For females only: pregnant or lactating women, where pregnancy is defined as the state of a female after conception and until termination of the gestation, confirmed by a positive serum human chorionic gonadotropin laboratory test. A serum pregnancy test is to be performed at screening and a urine pregnancy test is to be performed prior to randomisation;\n19. Use of any kind of electronic smoking devices within 6 months prior to screening.\n\nPart I BE subjects Inclusion Criteria:\n\n1. Signed and dated informed consent obtained prior to any study-related procedure;\n2. Male or female subject ≥18 and ≤80 years of age at screening;\n3. Clinical history consistent with BE (cough, chronic sputum production, and\u002For recurrent respiratory infections) that is confirmed by chest computed tomography (CT) demonstrating BE affecting 1 or more lobes (confirmation may be based on prior chest CT); subjects whose past chest radiographic image records or report are not available will undergo chest CT scan during screening;\n4. Post-bronchodilator FEV1 ≥50% of the predicted value at screening;\n5. If currently receiving treatment for BE, this treatment should be administered at a stable dose;\n6. Subjects in a stable clinical condition with no exacerbation of BE for at least 4 weeks prior to randomisation. A pulmonary exacerbation is defined as a deterioration in three or more of the key symptoms for at least 48 hours (cough, sputum volume and\u002For consistency, sputum purulence, breathlessness and\u002For exercise tolerance, fatigue and\u002For malaise, haemoptysis) AND a clinician-prescribed course of antibiotics;\n7. Vital signs within normal limits at screening and prior to randomisation: DBP ≥40 and ≤89 mmHg, and SBP ≥90 and ≤150 mmHg; body temperature \\\u003C37.5°C;\n8. Ability to understand the study procedures and the risks involved, and the ability to be trained to use the inhalers correctly and to generate sufficient PIF (at least 40 L\u002Fmin) using the In-Check Dial set as per \"GenuAir\" inhaler resistance, at screening;\n9. Male subjects willing to use a male condom throughout the study if they have WOCBP partners; male subjects with non-WOCBP partners or who are sterile do not have contraception requirements;\n10. Female subjects (if WOCBP) and\u002For their partners (if fertile) must be willing to use a highly effective birth control method, preferably with low user dependency, throughout the study; female subjects who are non-WOCBP or who have non-fertile partners do not have contraception requirements.\n\nPart I BE subjects Exclusion Criteria:\n\n1. History of a clinically meaningful unstable or uncontrolled chronic comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering the study drug to the subject;\n2. Acute symptomatic respiratory tract infection which constitutes an increase from the subject's baseline, per the investigator's judgment, within 4 weeks prior to randomisation;\n3. Abnormal and clinically significant 12-lead ECG at screening or prior to randomisation that results in an active medical problem, which may impact the safety of the subject, per the investigator's judgment. Male subjects with QTcF \\>450 ms and female subjects with QTcF \\>470 ms cannot be enrolled;\n4. Clinically significant abnormal laboratory values at screening that, in the opinion of the investigator, may put the subject at risk by participating in the study, or interfere with the subject's treatment or assessment, or influence the results of the study;\n5. Participation in another clinical study, where investigational drug was received less than 30 days or less than 5 half-lives of the previous administered product (whichever is longer) prior to screening; participation in another clinical study is also not allowed between screening and randomisation;\n6. Primary diagnosis of asthma, as determined by the investigator;\n7. Concomitant diagnosis of cystic fibrosis;\n8. Diagnosis of chronic obstructive pulmonary disease (COPD) made by a clinician, with airflow obstruction (post-bronchodilator FEV1\u002FFVC ratio \\\u003C0.7) and at least a 10 pack-year smoking history; subjects with documented COPD but without airflow obstruction or smoking history will be permitted;\n9. Current smokers; ex-smokers must have stopped for at least 1 year prior to screening (≥6 months for electronic smoking devices);\n10. Subjects with an active tuberculous mycobacteria (TM) or non-tuberculous mycobacteria (NTM) infection requiring or receiving antibiotic treatment, an active allergic bronchopulmonary aspergillosis requiring treatment with corticosteroids or anti-fungal therapy, and\u002For a connective tissue disease (CTD) receiving an immunosuppressive treatment equivalent to \\>10 mg prednisolone daily or systemic immunosuppression;\n11. Diagnosis of common variable immunodeficiency (CVID) or other immunodeficiencies requiring immunoglobulin treatment, based on subject history;\n12. Diagnosis of rheumatoid arthritis;\n13. Malignancy that has not been in complete remission for at least 1 year or any untreated localised carcinomas;\n14. History of solid organ\u002Fhaematological transplantation and receiving immunosuppressive therapy;\n15. Use of any antimicrobials (oral, inhaled, or intravenous) within 4 weeks prior to randomisation, except for subjects who are on stable treatment with macrolide antibiotics (for at least 3 months);\n16. Medical history of discontinuation of previous inhaled therapy due to bronchospasm or intolerance;\n17. Documented COVID-19 diagnosis within 4 weeks prior to randomisation, or associated complications\u002Fsymptoms;\n18. Diagnosis of alpha-1-antitrypsin (AAT) deficiency defined as an AAT serum level \\\u003C110 mg\u002FdL; a prior test result of AAT serum level to confirm the diagnosis will be acceptable. In the event that a prior result is not available, a new test will be performed during the screening period and the result considered for the eligibility at randomisation.\n19. Treatment with prohibited concomitant medications or if the subject is expected to take prohibited concomitant medications during the study;\n20. Subjects treated with monoclonal antibodies (mAbs) for any respiratory conditions;\n21. Subjects with traction BE;\n22. For females only: pregnant or lactating women, where pregnancy is defined as the state of a female after conception and until termination of the gestation, confirmed by a positive serum human chorionic gonadotropin laboratory test. A serum pregnancy test is to be performed at screening, and a urine pregnancy test is to be performed prior to randomisation;\n23. Positive HIV1 or HIV2 serology results at screening;\n24. Hepatitis serology results which indicate acute or chronic HB or HCV at screening;\n25. BMI ≤17 kg\u002Fm2 at screening.\n\nPart II BE subjects Inclusion Criteria: the subjects must meet all the inclusion criteria listed in Part I for subjects with BE (Cohort B), except the inclusion criterion below:\n\n4\\. Post-bronchodilator FEV1 ≥30% of the predicted value at screening.\n\nThe subjects must also meet the additional inclusion criteria listed below:\n\n11\\. Subjects who are regular daily sputum producers and who are able to provide at least one sputum sample at screening and two sputum samples prior to randomisation; 12. Subjects with active NE level in sputum sample at screening, defined by either a positive bacterial culture in a local laboratory (a positive result for any pathogen will be accepted for eligibility) or by a positive reading of the NEATstik® research use only test.\n\nPart II BE subjects Exclusion Criteria:\n\nSee the list of criteria in Part I for subjects with BE (Cohort B), except the exclusion criterion below:\n\n15\\. Use of oral or inhaled antibiotics \\\u003C 3 months prior to randomization as chronic treatment for BE. Patients on antibiotics as chronic treatment should have been on such treatment for ≥ 3 months prior to randomization while meeting all other inclusion and exclusion criteria.",{"count":80,"type":22},[551,61],"PHASE1","The aim of this clinical trial is to assess the safety of:\n\n* single doses of the study drug CHF6333 in Healthy Volunteers (HVs) and in subjects with Bronchiectasis (BE) - Part I\n* repeated doses of the study drug CHF6333 in subjects with BE - Part II",[26],"2026-03-04",{"date":556,"type":41},"2026-03-05",{"date":558,"type":41},"2023-11-29",{"date":560,"type":22},"2026-08",{"name":126,"class":79},9,{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":569,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":571,"conditions":572,"keywords":574,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":47},"100268865","evaluation-of-the-lung-microbiome-in-ntm-bronchiectasis-100268865","NCT02779478","Evaluation Of The Lung Microbiome In NTM Bronchiectasis","Inclusion Criteria:\n\n* History of pulmonary symptoms: cough, fatigue, malaise, fever, weight loss, dyspnea, hemoptysis, or chest discomfort\n* Imaging abnormalities (within 2 years): defined as nodular or cavitary opacities on chest radiograph, or a computed tomography scan that shows bronchiectasis or bronchial wall thickening with associated multiple small nodules.\n\nDefinition of NTM case:\n\n* Subjects that meet inclusion criteria and have culture positivity for NTM: at least two separate expectorated induced sputum samples or from one bronchoalveolar lavage (BAL) or lung biopsy\n\nDefinition of NTM control:\n\n* Subjects that meet inclusion criteria and have less than two separate expectorated induced sputum samples culture negative or culture negative bronchoalveolar lavage (BAL) or lung biopsy.\n\nExclusion Criteria for cohort study (Aim 1-2):\n\n* Recent (\\\u003C1 months prior) oral antibiotic or steroid use. (Continuous treatment with macrolides and inhaled steroids are acceptable \\>1 month prior)\n* Recent smoking history\n\nExclusion Criteria for bronchoscopic study (Aims 3-4):\n\n* Forced expiratory volume at one second (FEV1) \\\u003C 70%of predicted.\n* Significant cardiovascular disease defined as abnormal EKG, known or suspected coronary artery disease or congestive heart failure.\n* Diabetes mellitus\n* Significant liver or renal disease\n* Severe coagulopathy (INR \\> 1.4, Partial Thromboplastin Time (PTT) \\> 40 seconds and platelet count \\\u003C 150x103 cells).\n* Pregnancy\n* Ethanol (ETOH) use of more than \\>6 beers or \\>4 mixed drinks daily\n* Lack of capacity to provide informed consent.",{"count":570,"type":22},1000,"A biomarker cohort study design is proposed to study whether specific airway microbiota alterations are associated with pulmonary Non-tuberculous mycobacteria (NTM) disease. In a cohort of 200 subjects suspected of having pulmonary NTM disease, the investigators will evaluate the airway microbiome using an aliquot of the induced sputum and upper airway samples. Since induced sputum may reflect different regions of the upper\u002Flower airways, the investigators will evaluate the upper and lower airway microbiome in a subgroup (case-control group) of patients using samples obtained through upper airway sampling and bronchoscopy, respectively.",[573,26],"Nontuberculous Mycobacteria",[575,576,577,578],"chronic obstructive pulmonary disease (COPD)","cavitary","nodular bronchiectatic disease","NTM","2026-02-26",{"date":581,"type":41},"2026-02-27",{"date":583,"type":41},"2014-10-01",{"date":585,"type":22},"2031-07",{"name":587,"class":165},"NYU Langone Health",{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":593,"acronym":594,"eligibilityCriteria":595,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":596,"targetDuration":4,"studyType":59,"phases":598,"briefSummary":599,"conditions":600,"keywords":602,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":606,"lastUpdatePostDateStruct":607,"startDateStruct":609,"completionDateStruct":611,"leadSponsor":613,"locationsCount":47},"100627014","simeox-200-us-study-100627014","NCT07443124","Simeox 200 US Study","A Pilot Study to Assess the Effects of Simeox 200 Airway Clearance Device in Bronchiectasis Patients With Chronic Mucus Hypersecretion","IMPACT","Inclusion Criteria:\n\n1. Diagnosis of bronchiectasis confirmed by computed chest tomography (CT chest) performed within the prior 36 months\n2. Persistent productive cough for which daily airway clearance therapy is prescribed.\n3. Daily sputum production estimated at \\> 1 tsp or 5 ml\n4. Clinically stable on medical regimen with no pulmonary exacerbation in the past 4 weeks prior to study enrolment\n5. Subject able to sign informed consent\n\nExclusion Criteria:\n\n1. Inability to cough forcefully and independently, as determined by the clinician\n2. Ventilatory assistance with endotracheal tube, tracheostomy tube, or mask (not including nocturnal CPAP)\n3. Neuromuscular disease with muscle respiratory weakness\n4. Severe restrictive lung disease defined as Forced Vital Capacity (FVC) \\\u003C60% of predicted\n5. Unstable cardiac disease (e.g. major cardiac arrhythmia, unstable heart failure, heart attack, unstable angina)\n6. Hemodynamic instability, as determined by the clinician\n7. Airway at risk for aspiration, as determined by the clinician\n8. Uncontrolled gastroesophageal reflux disease (GERD) as determined by the clinician\n9. Upper airway surgery in the prior 3 months\n10. Cardiothoracic surgery, including esophageal surgery, in the prior 6 months\n11. Anticipated hospitalization within the next 2 weeks\n12. History of pneumothorax within the prior 6 months\n13. History of haemoptysis treated with embolization within the prior 12 months\n14. Inability to use airway clearance therapy as directed\n15. Unable or unwilling to complete study visits or provide follow-up data as required per the study protocol\n16. Pregnant or lactating female",{"count":597,"type":22},35,[148],"The purpose of this single arm post-market observational study is to evaluate the short-term effectiveness of the Simeox 200 airway clearance device in improving airway clearance in adult patients aged 18 to 85 with bronchiectasis and chronic mucus hypersecretion. The study aims to establish a baseline for wet sputum weight production using the Simeox 200 device. Additionally, the study aims to assess the short-term effects of Simeox 200 on various outcomes, including lung function, respiratory symptoms, and health-related quality of life.\n\nThe study participants will undergo the following steps:\n\n1. Baseline Visit (V0): Participants will attend a baseline visit for eligibility screening, consent, a physical exam, and baseline assessments of various relevant parameters such as lung function, SpO2, and Patient-Reported-Outcomes.\n2. Treatment Sessions (V1): Participants will perform two supervised treatment sessions with the Simeox 200 device at the clinic, during which sputum will be collected and weighed.\n3. Home Use : Participants will use the device at home twice daily for 2 weeks, recording their usage and symptoms in a daily electronic diary.\n4. Final Clinic Visit (V2): Participants will return for a final clinic visit for repeat assessments.\n5. Follow-up Phone Call (14 days after V2): Participants will receive a follow-up phone call to assess ongoing symptoms and health status.",[26,601],"Mucus; Plug",[26,603,604,605],"Mucus hypersecretion","Airway clearance technique","Bronchial drainage","2026-02-24",{"date":608,"type":41},"2026-03-02",{"date":610,"type":22},"2026-02",{"date":612,"type":22},"2026-06",{"name":614,"class":79},"Inogen Inc.",{"id":616,"slug":617,"hasResults":12,"nctId":618,"briefTitle":619,"officialTitle":619,"acronym":620,"eligibilityCriteria":621,"healthyVolunteers":16,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":622,"targetDuration":624,"studyType":23,"phases":4,"briefSummary":625,"conditions":626,"keywords":627,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":642,"locationsCount":47},"100614056","a-cohort-for-inflammatory-respiratory-diseases-from-phenotyping-to-personalised-medicine-100614056","NCT07274631","A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine","PALMIRE","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Follow-up for one of the following conditions: asthma, COPD, bronchiectasis (DDB), cystic fibrosis (CF), primary ciliary dyskinesia (PCD), or interstitial lung diseases (ILD)\n* Healthy volunteers (controls)\n\nExclusion Criteria:\n\n* Subjects protected by law (e.g., legal incapacity)\n* Any condition preventing informed consent or participation",{"count":623,"type":22},470,"10 Years","Chronic inflammatory pulmonary diseases, including asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, cystic fibrosis (CF), primary ciliary dyskinesia (PCD) and interstitial lung diseases (ILD) are characterised by lung inflammation and remodelling. Clinical, functional, microbiological, biological, pathological and prognostic features are highly variable and heterogeneous. Several phenotypes have been described within the same pathology, as similar phenotypic traits between different pathologies, or the coexistence of components of several diagnoses in the same patient, suggesting shared underlying mechanisms that could represent new therapeutic targets, beyond the initial medical diagnosis.\n\nThe objectives of this prospective study are to analyze the phenotypic characteristics (clinical, demographic, biological, morphological, pathological, and microbiological characteristics) together with respiratory exposures and underlying mechanisms involving airway epithelium and inflammation processes in a cohort of patients diagnosed with asthma, COPD, bronchiectasis, CF, PCD and ILD.",[154,152,26,27,35],[628,152,26,629,630,631,632,633,634],"Chronic obstructive pulmonary disease","Cystic fibrosis","Primary ciliary dyskinesia","Airway microbiota","Airway epithelium","Remodeling","Exposome","2026-02-18",{"date":637,"type":41},"2026-02-20",{"date":639,"type":41},"2025-09-15",{"date":641,"type":22},"2040-09-15",{"name":643,"class":165},"CHU de Reims"]